Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
JAK3 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
JAK3 target evaluation report from PatSnap MCP data, evaluating common gamma-chain cytokine signaling, validation evidence, competition, IP, and R&D strategy.
Latest Hotspot
8 min read
JAK1 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
JAK1 target evaluation report generated with PatSnap MCP data, covering cytokine signaling biology, validation evidence, competitive landscape, IP, and R&D strategy.
Latest Hotspot
8 min read
CSF3R Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
CSF3R target evaluation report built from PatSnap MCP data, assessing G-CSF receptor biology, clinical validation, competition, IP, and R&D strategy.
Latest Hotspot
8 min read
PDGFRB Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
PDGFRB target evaluation report generated from PatSnap MCP data, covering PDGFR beta biology, clinical evidence, competition, IP, and R&D strategy.
Latest Hotspot
8 min read
PDGFRA Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
PDGFRA target evaluation report generated from PatSnap MCP data, assessing PDGFR alpha biology, clinical evidence, competition, IP, and R&D strategy.
Latest Hotspot
8 min read
KIT Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
KIT target evaluation report built from PatSnap MCP data, covering c-Kit biology, clinical validation, competitive intensity, IP, and R&D strategy.
Latest Hotspot
8 min read
ABL2 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
ABL2 target evaluation report generated with PatSnap MCP data, reviewing ABL2 biology, validation gap, competition, IP, and R&D strategy.
Latest Hotspot
8 min read
ABL1 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
ABL1 target evaluation report using PatSnap Life Sciences MCP data, assessing ABL1 biology, clinical evidence, competition, IP, and R&D strategy.
Latest Hotspot
8 min read
PIM3 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
PIM3 target evaluation report generated from PatSnap MCP data, covering Pim-3 biology, clinical evidence, competitive context, IP, and R&D strategy.
Latest Hotspot
8 min read
PIM2 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
PIM2 target evaluation report generated from PatSnap MCP data, evaluating Pim-2 biology, validation evidence, competition, IP, and R&D strategy.
Latest Hotspot
8 min read
PIM1 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
PIM1 target evaluation report generated with PatSnap Life Sciences MCP data, covering proto-oncogene kinase biology, clinical evidence, competition, IP, and R&D strategy.
Latest Hotspot
8 min read
PRKCD Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
PRKCD target evaluation report based on PatSnap MCP data, covering PKC delta biology, validation evidence, competitive landscape, IP, and R&D recommendations.